New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis

Qiang Ding, Tracy Luckhardt, Louise Hecker, Yong Zhou, Gang Liu, Veena B. Antony, Joao DeAndrade, Victor J. Thannickal

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the idiopathic interstitial pneumonias. There are currently no effective pharmacological therapies approved for the treatment of IPF. Despite the focus on targeting fibrogenic pathways, recent clinical trials have been largely disappointing. Progress is being made in elucidating key cellular processes and molecular pathways critical to IPF pathogenesis, and this should facilitate the development of more effective therapeutics for this recalcitrant disease. Emerging pathobiological concepts include the role of aging and cellular senescence, oxidative stress, endoplasmic reticulum stress, cellular plasticity, microRNAs and mechanotransduction. Therapeutic approaches that target molecular pathways to modulate aberrant cellular phenotypes and promote tissue homeostasis in the lung must be developed. Heterogeneity in biological and clinical phenotypes of IPF warrants a personalized medicine approach to diagnosis and treatment of this lung disorder.

Original languageEnglish (US)
Pages (from-to)981-1001
Number of pages21
JournalDrugs
Volume71
Issue number8
DOIs
StatePublished - 2011
Externally publishedYes

Fingerprint

Idiopathic Pulmonary Fibrosis
Cellular Mechanotransduction
Idiopathic Interstitial Pneumonias
Phenotype
Therapeutics
Lung
Precision Medicine
Endoplasmic Reticulum Stress
Critical Pathways
Cell Aging
MicroRNAs
Oxidative Stress
Homeostasis
Clinical Trials
Pharmacology

Keywords

  • Acetylcysteine
  • Anticoagulants
  • Azathioprine
  • Bosentan
  • Corticosteroids
  • Etanercept
  • Idiopathic-pulmonary-fibrosis
  • Imatinib
  • Interferon
  • Interferon-gamma
  • Oxygen
  • Pirfenidone
  • Prednisone
  • Sildenafil.

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Ding, Q., Luckhardt, T., Hecker, L., Zhou, Y., Liu, G., Antony, V. B., ... Thannickal, V. J. (2011). New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis. Drugs, 71(8), 981-1001. https://doi.org/10.2165/11591490-000000000-00000

New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis. / Ding, Qiang; Luckhardt, Tracy; Hecker, Louise; Zhou, Yong; Liu, Gang; Antony, Veena B.; DeAndrade, Joao; Thannickal, Victor J.

In: Drugs, Vol. 71, No. 8, 2011, p. 981-1001.

Research output: Contribution to journalArticle

Ding, Q, Luckhardt, T, Hecker, L, Zhou, Y, Liu, G, Antony, VB, DeAndrade, J & Thannickal, VJ 2011, 'New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis', Drugs, vol. 71, no. 8, pp. 981-1001. https://doi.org/10.2165/11591490-000000000-00000
Ding, Qiang ; Luckhardt, Tracy ; Hecker, Louise ; Zhou, Yong ; Liu, Gang ; Antony, Veena B. ; DeAndrade, Joao ; Thannickal, Victor J. / New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis. In: Drugs. 2011 ; Vol. 71, No. 8. pp. 981-1001.
@article{ac457c781a154ed188c781c51f78f9ef,
title = "New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis",
abstract = "Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the idiopathic interstitial pneumonias. There are currently no effective pharmacological therapies approved for the treatment of IPF. Despite the focus on targeting fibrogenic pathways, recent clinical trials have been largely disappointing. Progress is being made in elucidating key cellular processes and molecular pathways critical to IPF pathogenesis, and this should facilitate the development of more effective therapeutics for this recalcitrant disease. Emerging pathobiological concepts include the role of aging and cellular senescence, oxidative stress, endoplasmic reticulum stress, cellular plasticity, microRNAs and mechanotransduction. Therapeutic approaches that target molecular pathways to modulate aberrant cellular phenotypes and promote tissue homeostasis in the lung must be developed. Heterogeneity in biological and clinical phenotypes of IPF warrants a personalized medicine approach to diagnosis and treatment of this lung disorder.",
keywords = "Acetylcysteine, Anticoagulants, Azathioprine, Bosentan, Corticosteroids, Etanercept, Idiopathic-pulmonary-fibrosis, Imatinib, Interferon, Interferon-gamma, Oxygen, Pirfenidone, Prednisone, Sildenafil.",
author = "Qiang Ding and Tracy Luckhardt and Louise Hecker and Yong Zhou and Gang Liu and Antony, {Veena B.} and Joao DeAndrade and Thannickal, {Victor J.}",
year = "2011",
doi = "10.2165/11591490-000000000-00000",
language = "English (US)",
volume = "71",
pages = "981--1001",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "8",

}

TY - JOUR

T1 - New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis

AU - Ding, Qiang

AU - Luckhardt, Tracy

AU - Hecker, Louise

AU - Zhou, Yong

AU - Liu, Gang

AU - Antony, Veena B.

AU - DeAndrade, Joao

AU - Thannickal, Victor J.

PY - 2011

Y1 - 2011

N2 - Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the idiopathic interstitial pneumonias. There are currently no effective pharmacological therapies approved for the treatment of IPF. Despite the focus on targeting fibrogenic pathways, recent clinical trials have been largely disappointing. Progress is being made in elucidating key cellular processes and molecular pathways critical to IPF pathogenesis, and this should facilitate the development of more effective therapeutics for this recalcitrant disease. Emerging pathobiological concepts include the role of aging and cellular senescence, oxidative stress, endoplasmic reticulum stress, cellular plasticity, microRNAs and mechanotransduction. Therapeutic approaches that target molecular pathways to modulate aberrant cellular phenotypes and promote tissue homeostasis in the lung must be developed. Heterogeneity in biological and clinical phenotypes of IPF warrants a personalized medicine approach to diagnosis and treatment of this lung disorder.

AB - Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the idiopathic interstitial pneumonias. There are currently no effective pharmacological therapies approved for the treatment of IPF. Despite the focus on targeting fibrogenic pathways, recent clinical trials have been largely disappointing. Progress is being made in elucidating key cellular processes and molecular pathways critical to IPF pathogenesis, and this should facilitate the development of more effective therapeutics for this recalcitrant disease. Emerging pathobiological concepts include the role of aging and cellular senescence, oxidative stress, endoplasmic reticulum stress, cellular plasticity, microRNAs and mechanotransduction. Therapeutic approaches that target molecular pathways to modulate aberrant cellular phenotypes and promote tissue homeostasis in the lung must be developed. Heterogeneity in biological and clinical phenotypes of IPF warrants a personalized medicine approach to diagnosis and treatment of this lung disorder.

KW - Acetylcysteine

KW - Anticoagulants

KW - Azathioprine

KW - Bosentan

KW - Corticosteroids

KW - Etanercept

KW - Idiopathic-pulmonary-fibrosis

KW - Imatinib

KW - Interferon

KW - Interferon-gamma

KW - Oxygen

KW - Pirfenidone

KW - Prednisone

KW - Sildenafil.

UR - http://www.scopus.com/inward/record.url?scp=79958788032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958788032&partnerID=8YFLogxK

U2 - 10.2165/11591490-000000000-00000

DO - 10.2165/11591490-000000000-00000

M3 - Article

C2 - 21668038

AN - SCOPUS:79958788032

VL - 71

SP - 981

EP - 1001

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 8

ER -